Neuphoria Therapeutics Inc. Company Profile
NASDAQ: NEUPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Neuphoria Therapeutics at a glance
Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Millis, MA. Neuphoria Therapeutics is led by Dr. Spyridon Papapetropoulos M.D., Ph.D. and employs about 1 people. The company's shares have traded publicly since 2021.
At a market capitalization of $12.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001191070, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Neuphoria Therapeutics do?
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Neuphoria Therapeutics Inc.
- Ticker
- NASDAQ: NEUP
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Spyridon Papapetropoulos M.D., Ph.D.
- Employees
- 1
- Headquarters
- 14 Milliston Road, Millis, MA, United States
- Phone
- 339 240 6066
- Website
- neuphoriatx.com
- IPO year
- 2021
- Market cap
- $12.50M
- SEC CIK
- 0001191070
- Latest annual report
- 10-K · Sep 18, 2026
Companies similar to Neuphoria Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALLRAllarity Therapeutics Inc. | 0.785 | -9.25% | $12.56M | vs NEUP |
| MCRBSeres Therapeutics Inc. | 1.24 | -6.77% | $12.64M | vs NEUP |
| MIRAMIRA Pharmaceuticals Inc. | 0.291 | -20.84% | $12.23M | vs NEUP |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs NEUP |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs NEUP |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs NEUP |
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs NEUP |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs NEUP |